Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | FPR1 | P21462 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27057711 | 0.87 | SCN9A (0.40) | PDE4BTRPV1SLC6A2FPR1FPR2 | |
| SCHEMBL25331737 | 0.83 | PDE4B (0.40) | PDE4BTRPV1GAASLC6A2P2RX7 | |
| SCHEMBL25330331 | 0.82 | SLC6A2 (0.55) | SLC6A2FPR1FPR2 | |
| SCHEMBL25379854 | 0.79 | FPR1 (0.41) | TRPV1GAASLC6A2ALDH1A1FPR1 | |
| SCHEMBL25331214 | 0.79 | FPR1 (0.41) | TRPV1GAASLC6A2ALDH1A1FPR1 | |
| SCHEMBL29073342 | 0.78 | TRPA1 (0.39) | PDE4BTRPV1SLC6A2ALDH1A1TSHR | |
| SCHEMBL3773883 | 0.77 | RIPK1 (0.38) | AADAT | |
| SCHEMBL25331370 | 0.74 | GAA (0.41) | GAASLC6A2ALDH1A1FPR1FPR2 | |
| SCHEMBL25380432 | 0.74 | SLC6A2 (0.48) | SLC6A2FPR1FPR2 | |
| SCHEMBL25331107 | 0.72 | SLC6A2 (0.40) | GAASLC6A2ALDH1A1FPR1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| EP-4222143-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | Katholieke Universiteit Leuven (BE) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | PDE4B 2327/4885TRPV1 3761/4885GAA 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.